Tamar Howson
director
Healthcare
Investiga
Angola
Biography
Tamar Howson has served as a director of Enzymotec since July 2015. Ms. Howson served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011, she worked for JSB-Partners, a transaction advisory firm, providing business development support to life sciences companies. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. Ms. Howson also held the position of Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007. Ms. Howson currently serves on the Board of Directors of publicly traded Organovo, Inc., OXiGENE, Inc. and Cynapsus, Inc. In the past, Ms. Howson served as a director of Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc., all of which are publicly traded. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She has also served on the boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept and HBA. Ms. Howson holds a bachelor’s degree in Chemical Engineering from the Technion, Israel, a MS from the City University of New York and an MBA from Columbia University.
Research Interest
Tamar Howson has served as a director of Enzymotec since July 2015. Ms. Howson served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011, she worked for JSB-Partners, a transaction advisory firm, providing business development support to life sciences companies. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. Ms. Howson also held the position of Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007. Ms. Howson currently serves on the Board of Directors of publicly traded Organovo, Inc., OXiGENE, Inc. and Cynapsus, Inc. In the past, Ms. Howson served as a director of Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc., all of which are publicly traded. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She has also served on the boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept and HBA. Ms. Howson holds a bachelor’s degree in Chemical Engineering from the Technion, Israel, a MS from the City University of New York and an MBA from Columbia University.
